Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

isosorbide mononitrate

- PMLiVE

Daily brief:  Trump fails to ruffle PBMs, pharma, Jowell leaves brain tumour research legacy

A rapid round-up of recent happenings, plus some key events taking place this week

- PMLiVE

AZ’s Fasenra hit by COPD trial failure

Results give advantage to respiratory rivals GSK

AstraZeneca AZ

Maintenance OK boosts AstraZeneca’s Lynparza in Europe

New pill formulation also helps AZ and MSD against competitors in PARP class

- PMLiVE

Redx poaches AstraZeneca senior executive

Lisa Anson joins the UK biotech as its CEO

- PMLiVE

Merck’s Keytruda scores in frontline lung cancer yet again

Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

AstraZeneca AZ

AZ pushes back data read-out from MYSTIC lung cancer trial

The delay could further undermine confidence in a positive outcome

- PMLiVE

AZ adds another Ionis drug in $330m kidney disease deal

The candidate targets a genetically associated form of the condition

The ‘Million Hour Challenge’

AstraZeneca employees save two million hours through simplification

AstraZeneca AZ

Clock starts ticking on AZ’s first-line lung cancer filing in US

FDA priority review of oncology treatment Tagrisso begins

- PMLiVE

UK trumpets life sciences post-Brexit ‘sector deal’

Highlights commitments from GlaxoSmithKline, AstraZeneca and MSD

AstraZeneca AZ

AZ speeds first-line lung cancer filing for Tagrisso to EMA

As FLAURA trial results show boosted progression-free survival

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links